1921
Volume 98, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

In –endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. , the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.17-0888
2018-03-05
2019-11-15
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/5/tpmd170888.html?itemId=/content/journals/10.4269/ajtmh.17-0888&mimeType=html&fmt=ahah

References

  1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team; , 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671. [Google Scholar]
  2. Coura-Vital W, 2014. Evaluation of change in canine diagnosis protocol adopted by the visceral leishmaniasis control program in Brazil and a new proposal for diagnosis. PLoS One 9: e91009. [Google Scholar]
  3. Millan J, Ferroglio E, Solano-Gallego L, , 2014. Role of wildlife in the epidemiology of Leishmania infantum infection in Europe. Parasitol Res 113: 20052014. [Google Scholar]
  4. Dantas-Torres F, Solano-Gallego L, Baneth G, Ribeiro VM, de Paiva-Cavalcanti M, Otranto D, , 2012. Canine leishmaniosis in the Old and New Worlds: unveiled similarities and differences. Trends Parasitol 28: 531538. [Google Scholar]
  5. Rock KS, Quinnell RJ, Medley GF, Courtenay O, , 2016. Progress in the mathematical modelling of visceral leishmaniasis. Adv Parasitol 94: 49131. [Google Scholar]
  6. Courtenay O, Quinnell RJ, Garcez LM, Shaw JJ, Dye C, , 2002. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 186: 13141320. [Google Scholar]
  7. Dye C, , 1996. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 55: 125130. [Google Scholar]
  8. Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Petersen CA, , 2013. Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol 191: 55425550. [Google Scholar]
  9. Boggiatto PM, Ramer-Tait AE, Metz K, Kramer EE, Gibson-Corley K, Mullin K, Hostetter JM, Gallup JM, Jones DE, Petersen CA, , 2010. Immunologic indicators of clinical progression during canine Leishmania infantum infection. Clin Vaccine Immunol 17: 267273. [Google Scholar]
  10. Schantz PM, Steurer FJ, Duprey ZH, Kurpel KP, Barr SC, Jackson JE, Breitschwerdt EB, Levy MG, Fox JC, , 2005. Autochthonous visceral leishmaniasis in dogs in North America. J Am Vet Med Assoc 226: 13161322. [Google Scholar]
  11. Gaskin AA, 2002. Visceral leishmaniasis in a New York foxhound kennel. J Vet Intern Med 16: 3444. [Google Scholar]
  12. Schaut RG, Robles-Murguia M, Juelsgaard R, Esch KJ, Bartholomay LC, Ramalho-Ortigao M, Petersen CA, , 2015. Vectorborne transmission of Leishmania infantum from hounds, United States. Emerg Infect Dis 21: 22092212. [Google Scholar]
  13. Petersen CA, , 2009. New means of canine leishmaniasis transmission in North America: the possibility of transmission to humans still unknown. Interdiscip Perspect Infect Dis 2009: 802712. [Google Scholar]
  14. Drahota J, Martin-Martin I, Sumova P, Rohousova I, Jimenez M, Molina R, Volf P, , 2014. Recombinant antigens from Phlebotomus perniciosus saliva as markers of canine exposure to visceral leishmaniases vector. PLoS Negl Trop Dis 8: e2597. [Google Scholar]
  15. Grinnage-Pulley T, Scott B, Petersen CA, , 2016. A mother’s gift: congenital transmission of Trypanosoma and Leishmania species. PLoS Pathog 12: e1005302. [Google Scholar]
  16. Palatnik-de-Sousa CB, , 2012. Vaccines for canine leishmaniasis. Front Immunol 3: 69. [Google Scholar]
  17. EMA, 2016. Letifend. EPAR. London, United Kingdom: European Union, 1–2.
  18. Palatnik-de-Sousa CB, , 2008. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26: 17091724. [Google Scholar]
  19. Vida B, Toepp A, Schaut RG, Esch KJ, Juelsgaard R, Shimak RM, Petersen CA, , 2016. Immunologic progression of canine leishmaniosis following vertical transmission in United States dogs. Vet Immunol Immunopathol 169: 3438. [Google Scholar]
  20. Schaut RG, Grinnage-Pulley TL, Esch KJ, Toepp AJ, Duthie MS, Howard RF, Reed SG, Petersen CA, , 2016. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant. Vaccine 34: 52255234. [Google Scholar]
  21. Regina-Silva S, Feres AM, Franca-Silva JC, Dias ES, Michalsky EM, de Andrade HM, Coelho EA, Ribeiro GM, Fernandes AP, Machado-Coelho GL, , 2016. Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil. Vaccine 34: 22332239. [Google Scholar]
  22. Testasicca MC, 2014. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population. Vet Parasitol 204: 169176. [Google Scholar]
  23. Fernandes AP, 2008. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 26: 58885895. [Google Scholar]
  24. Starita C, Gavazza A, Lubas G, , 2016. Hematological, biochemical, and serological findings in healthy canine blood donors after the administration of CaniLeish® vaccine. Vet Med Int 2016: 4601893. [Google Scholar]
  25. Oliva G, 2014. A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naive dogs exposed to two Leishmania infantum transmission seasons. PLoS Negl Trop Dis 8: e3213. [Google Scholar]
  26. Martin V, Vouldoukis I, Moreno J, McGahie D, Gueguen S, Cuisinier AM, , 2014. The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later. Vet Res (Faisalabad) 45: 69. [Google Scholar]
  27. European Commission, 2016. Community Register of Veterinary Medicinal Products. Available at: http://ec.europa.eu/health/documents/community-register/html/alfvreg.htm. Accessed April 5, 2017.
  28. Fernandes CB, Junior JT, de Jesus C, Souza BM, Larangeira DF, Fraga DB, Tavares Veras PS, Barrouin-Melo SM, , 2014. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis. Vaccine 32: 12871295. [Google Scholar]
  29. Moore GE, Guptill LF, Ward MP, Glickman NW, Faunt KK, Lewis HB, Glickman LT, , 2005. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc 227: 11021108. [Google Scholar]
  30. Yao PJ, Stephenson N, Foley JE, Toussieng CR, Farver TB, Sykes JE, Fleer KA, , 2015. Incidence rates and risk factors for owner-reported adverse events following vaccination of dogs that did or did not receive a Leptospira vaccine. J Am Vet Med Assoc 247: 11391145. [Google Scholar]
  31. Reis AB, Martins-Filho OA, Teixeira-Carvalho A, Giunchetti RC, Carneiro CM, Mayrink W, Tafuri WL, Correa-Oliveira R, , 2009. Systemic and compartmentalized immune response in canine visceral leishmaniasis. Vet Immunol Immunopathol 128: 8795. [Google Scholar]
  32. Ciaramella P, Oliva G, Luna RD, Gradoni L, Ambrosio R, Cortese L, Scalone A, Persechino A, , 1997. A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum. Vet Rec 141: 539543. [Google Scholar]
  33. Pattabhi S, 2010. Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis 4: pii: e822. [Google Scholar]
  34. Grimaldi G, Jr. Teva A, Ferreira AL, dos Santos CB, Pinto I, de-Azevedo CT, Falqueto A, , 2012. Evaluation of a novel chromatographic immunoassay based on Dual-Path Platform technology (DPP® CVL rapid test) for the serodiagnosis of canine visceral leishmaniasis. Trans R Soc Trop Med Hyg 106: 5459. [Google Scholar]
  35. Costa CH, , 2011. How effective is dog culling in controlling zoonotic visceral leishmaniasis? A critical evaluation of the science, politics and ethics behind this public health policy. Rev Soc Bras Med Trop 44: 232242. [Google Scholar]
  36. Costa DN, Codeco CT, Silva MA, Werneck GL, , 2013. Culling dogs in scenarios of imperfect control: realistic impact on the prevalence of canine visceral leishmaniasis. PLoS Negl Trop Dis 7: e2355. [Google Scholar]
  37. Croft SL, Sundar S, Fairlamb AH, , 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111126. [Google Scholar]
  38. Werneck GL, , 2014. Visceral leishmaniasis in Brazil: rationale and concerns related to reservoir control. Rev Saude Publica 48: 851856. [Google Scholar]
  39. Werneck GL, Costa CH, de Carvalho FA, Pires e Cruz Mdo S, Maguire JH, Castro MC, , 2014. Effectiveness of insecticide spraying and culling of dogs on the incidence of Leishmania infantum infection in humans: a cluster randomized trial in Teresina, Brazil. PLoS Negl Trop Dis 8: e3172. [Google Scholar]
  40. Miro G, Cardoso L, Pennisi MG, Oliva G, Baneth G, , 2008. Canine leishmaniosis–new concepts and insights on an expanding zoonosis: part two. Trends Parasitol 24: 371377. [Google Scholar]
  41. Manna L, Reale S, Vitale F, Picillo E, Pavone LM, Gravino AE, , 2008. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Vet J 177: 279282. [Google Scholar]
  42. Noli C, Auxilia ST, , 2005. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol 16: 213232. [Google Scholar]
  43. Costa PL, Dantas-Torres F, da Silva FJ, Guimaraes VC, Gaudencio K, Brandao-Filho SP, , 2013. Ecology of Lutzomyia longipalpis in an area of visceral leishmaniasis transmission in north-eastern Brazil. Acta Trop 126: 99102. [Google Scholar]
  44. Sundar S, Chakravarty J, , 2015. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother 16: 237252. [Google Scholar]
  45. Murray HW, , 2001. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 45: 21852197. [Google Scholar]
  46. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, , 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 11041107. [Google Scholar]
  47. Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S, , 2003. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 97: 350354. [Google Scholar]
  48. Musa A, 2012. Sodium stibogluconate (SSG) and paromomycin combination compared to SSG for visceral leishmaniasis in east Africa: a randomised controlled trial. PLoS Negl Trop Dis 6: e1674. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0888
Loading
/content/journals/10.4269/ajtmh.17-0888
Loading

Data & Media loading...

Supplemental Figures

  • Received : 15 Nov 2017
  • Accepted : 22 Jan 2018
  • Published online : 05 Mar 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error